1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Servier and Galapagos join hands in $2m-now, $260m-later oncology deal

 
• By Pial Ganguli

French company Servier and Belgium's Galapagos have entered into a multi-year strategic alliance to discover and develop new small molecule therapies for cancer, building on their existing relationship in the field of osteoarthritis.

French company Servier and Belgium's Galapagos have entered into a multi-year strategic alliance to discover and develop new small molecule therapies for cancer, building on their existing relationship in the field of osteoarthritis.

Under the latest agreement, Galapagos will receive research access payments of €2 million from Servier. Galapagos is also eligible for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By Manas Mishra

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.